These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29945212)

  • 21. Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?
    Bauersachs R; Zannad F
    Thromb Haemost; 2018 May; 118(S 01):S12-S22. PubMed ID: 29566413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review.
    Parascandolo E; Eisen A
    Expert Rev Cardiovasc Ther; 2020 Sep; 18(9):577-585. PubMed ID: 32755422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
    Windecker S; Tijssen J; Giustino G; Guimarães AH; Mehran R; Valgimigli M; Vranckx P; Welsh RC; Baber U; van Es GA; Wildgoose P; Volkl AA; Zazula A; Thomitzek K; Hemmrich M; Dangas GD
    Am Heart J; 2017 Feb; 184():81-87. PubMed ID: 27892890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
    Vanassche T; Verhamme P; Anand SS; Shestakovska O; Fox KA; Bhatt DL; Avezum A; Alings M; Aboyans V; Maggioni AP; Widimsky P; Berkowitz SD; Yusuf S; Connolly SJ; Eikelboom JW; Bosch J
    Eur J Prev Cardiol; 2020 Feb; 27(3):296-307. PubMed ID: 31615291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual antiplatelet therapy in the secondary prevention of atherothrombosis: need for new therapeutic approaches.
    Sabatier B; Trinquart L; Emmerich J
    Arch Cardiovasc Dis; 2010 Oct; 103(10):497-501. PubMed ID: 21130962
    [No Abstract]   [Full Text] [Related]  

  • 26. Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.
    Nicholls SJ; Nelson AJ
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):343-348. PubMed ID: 30680652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS.
    Bhagirath VC; Eikelboom JW; Anand SS
    Future Cardiol; 2018 Nov; 14(6):443-453. PubMed ID: 30417662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
    Shah R; Hellkamp A; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Fox KA; Nessel CC; Mahaffey KW; Piccini JP; Singer DE; Patel MR;
    Am Heart J; 2016 Sep; 179():77-86. PubMed ID: 27595682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy.
    Sharma M; Hart RG; Smith EE; Bosch J; Eikelboom JW; Connolly SJ; Dyal L; Reeh KW; Casanova A; Diaz R; Lopez-Jaramillo P; Ertl G; Störk S; Dagenais GR; Lonn EM; Ryden L; Tonkin AM; Varigos JD; Bhatt DL; Branch KRH; Probstfield JL; Kim JH; O'Donnell M; Vinereanu D; A A Fox K; Liang Y; Liu L; Zhu J; Pogosova N; Maggioni AP; Avezum A; Piegas LS; Keltai K; Keltai M; Berkowitz SD; Yusuf S
    Stroke; 2020 Oct; 51(10):2901-2909. PubMed ID: 32951537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients with Peripheral Artery Disease in the COMPASS Trial.
    Kruger PC; Anand SS; de Vries TAC; Eikelboom JW
    Eur J Vasc Endovasc Surg; 2018 Dec; 56(6):772-773. PubMed ID: 30213508
    [No Abstract]   [Full Text] [Related]  

  • 31. Rivaroxaban in peripheral artery disease: The new kid on the block?
    Hussain MA; Verma S; Al-Omran M
    J Vasc Surg; 2018 Mar; 67(3):985-986. PubMed ID: 29477208
    [No Abstract]   [Full Text] [Related]  

  • 32. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
    Greenberg B; Neaton JD; Anker SD; Byra WM; Cleland JGF; Deng H; Fu M; La Police DA; Lam CSP; Mehra MR; Nessel CC; Spiro TE; van Veldhuisen DJ; Vanden Boom CM; Zannad F
    JAMA Cardiol; 2019 Jun; 4(6):515-523. PubMed ID: 31017637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.
    Dangas GD; Tijssen JGP; Wöhrle J; Søndergaard L; Gilard M; Möllmann H; Makkar RR; Herrmann HC; Giustino G; Baldus S; De Backer O; Guimarães AHC; Gullestad L; Kini A; von Lewinski D; Mack M; Moreno R; Schäfer U; Seeger J; Tchétché D; Thomitzek K; Valgimigli M; Vranckx P; Welsh RC; Wildgoose P; Volkl AA; Zazula A; van Amsterdam RGM; Mehran R; Windecker S;
    N Engl J Med; 2020 Jan; 382(2):120-129. PubMed ID: 31733180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
    Anderson DR; Dunbar M; Murnaghan J; Kahn SR; Gross P; Forsythe M; Pelet S; Fisher W; Belzile E; Dolan S; Crowther M; Bohm E; MacDonald SJ; Gofton W; Kim P; Zukor D; Pleasance S; Andreou P; Doucette S; Theriault C; Abianui A; Carrier M; Kovacs MJ; Rodger MA; Coyle D; Wells PS; Vendittoli PA
    N Engl J Med; 2018 Feb; 378(8):699-707. PubMed ID: 29466159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.
    Lamy A; Eikelboom J; Sheth T; Connolly S; Bosch J; Fox KAA; Zhu J; Lonn E; Dagenais G; Widimsky P; Branch KRH; Bhatt DL; Zheng Z; Straka Z; Dagenais F; Kong Y; Marsden T; Lee SF; Copland I; Yusuf S
    J Am Coll Cardiol; 2019 Jan; 73(2):121-130. PubMed ID: 30654882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aspirin and women--age matters. Aspirin can help healthy women over age 56 prevent both strokes and heart attacks. For younger women, the hazards of aspirin outweigh the benefits.
    Harv Heart Lett; 2005 May; 15(9):1-2. PubMed ID: 15898147
    [No Abstract]   [Full Text] [Related]  

  • 37. Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
    Sheth MS; Yu B; Chu A; Porter J; Tam DY; Ferreira-Legere LE; Goodman SG; Farkouh ME; Ko DT; Abdel-Qadir H; Udell JA
    J Am Heart Assoc; 2022 Dec; 11(24):e026553. PubMed ID: 36515238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response by Fox to Letter Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease".
    Fox KAA
    Circulation; 2021 Jan; 143(1):e3. PubMed ID: 33378237
    [No Abstract]   [Full Text] [Related]  

  • 39. Triple therapy: worth the risk?
    Wernly B; Lichtenauer M; Hoppe UC; Lauten A; Navarese EP; Jung C
    Minerva Med; 2018 Oct; 109(5):403-405. PubMed ID: 30338683
    [No Abstract]   [Full Text] [Related]  

  • 40. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
    Tangelder MJ; Nwachuku CE; Jaff M; Baumgartner I; Duggal A; Adams G; Ansel G; Grosso M; Mercuri M; Shi M; Minar E; Moll FL
    J Endovasc Ther; 2015 Apr; 22(2):261-8. PubMed ID: 25809373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.